Name:
Donanemab Protein
Synonyms:
Species Name:
null
Label Name:
null
Marker Name:
Unconjugated
Accession:
Gene Id:
Molecular Weight:
25-27 kDa (Light Chain) & 53-55 kDa (Heavy Chain) (Reducing)
Purity:
＞95% by SDS-PAGE
Physical Appearance Name:
Lyophilized Powder
Endotoxin Name:
<0.1EU/μg
Reconstitution:
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
Stability Storage:
·12 months from date of receipt, -20 to -70 °C as supplied. ·1 month, 2 to 8 °C under sterile conditions after reconstitution. ·Please avoid repeated freeze-thaw cycles.
Buffer System:
PBS, pH7.4,5% trehalose
Quality Statement:
Donanemab is a humanized antibody and acts against the N-truncated pyroglutamate amyloid-β peptide at position 3 (pGlu3-Aβ, AβpE3) and is currently being investigated as a treatment for AD. Approaches to target pGlu3-Aβ have so far included the reduction in pGlu3-Aβ formation at the glutamyl cyclase (QC) catalyzing of N-truncated Aβ to form pGlu-Aβ and anti-pGlu3-Aβ antibodies. Antibodies including Donanemab aim to clear pGlu-Aβ after formation and/or blocking aggregation. AβpE3 antibodies have different binding properties against either soluble or aggregated conformations of AβpE3-42. Donenemab has been shown to have strong action with amyloid plaques, specifically cored plaques in the CNS. There is, however, a lack of clarity regarding its beneficial effects for AD therapy.
Reference:
1. Areeba Rashad, Atta Rasool, Muhammad Shaheryar, Azza Sarfraz, Zouina Sarfraz. Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials. Healthcare (Basel). 2022 Dec 22;11(1):32. doi: 10.3390/healthcare11010032.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
LAMP1/CD107a ProteinMedChemExpress
Glypican-1/GPC1 Proteinmedchemexpress
Popular categories:
TGF-β Receptor 1
SARS-CoV-2 Non-structural Protein 2
